Metraipolis › archive › dc_3549870db654
Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma — Europe PMC PMID:41588734
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41588734
- DOI
- 10.1002/cam4.71552
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T08:35:02.054Z
- SHA-256 of the archived text
44c2441608072947d82d3c9d869cbe2193c2e5cbfcf53f27aff6e7a9dddd9161- Stable URL of this page
https://metraipolis.com/documento/dc_3549870db654
How to cite
Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma — Europe PMC PMID:41588734 — Europe PMC (en), https://europepmc.org/article/MED/41588734 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3549870db654 (Metraipolis archive dc_3549870db654, sha256 44c2441608072947d82d3c9d869cbe2193c2e5cbfcf53f27aff6e7a9dddd9161)
BibTeX
@misc{dc3549870db654,
title = {Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma — Europe PMC PMID:41588734},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41588734},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3549870db654; sha256 44c2441608072947d82d3c9d869cbe2193c2e5cbfcf53f27aff6e7a9dddd9161},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41588734. Agents can read the archived copy with the MCP tool read_document.